What question did this study set out to answer?

The study aims to evaluate pathologic complete response (pCR) rates across molecular subtypes of breast cancer and their association with survival outcomes.

February 19, 2026Clinical Cancer Research

Abstract PS2-06-10: Pathologic Complete Response by Breast Cancer Molecular Subtype in a Colombian Cohort: Real-World Evidence from Latin America

View Full Paper

Ask AI

Bookmark

The study aims to evaluate pathologic complete response (pCR) rates across molecular subtypes of breast cancer and their association with survival outcomes.
Conducted a retrospective study of 488 patients with stage I-III breast cancer receiving neoadjuvant therapy and surgery.
Molecular subtypes were assigned using immunohistochemistry and FISH methods.
pCR was defined as ypT0/Tis ypN0; survival analyses employed Kaplan–Meier and log-rank tests.
Overall pCR rate was 34.6%, varying significantly by molecular subtype (60.3% in HER2-enriched).
pCR rates were higher in ER-negative (50.0%) and PR-negative tumors (49.1%).
Patients achieving pCR showed lower recurrence rates (4.7% vs. 12.9%) and improved disease-free survival compared to those who did not.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

This retrospective study evaluates pathologic complete response rates in breast cancer subtypes, highlighting implications for treatment strategies in Latin America.

Cite This Study

Velasco et al. (2026) studied this question.

synapsesocial.com/papers/6996a85cecb39a600b3ef0a1 https://doi.org/10.1158/1557-3265.sabcs25-ps2-06-10

View Full Paper

Ask AI

Bookmark

Implication

This retrospective study evaluates pathologic complete response rates in breast cancer subtypes, highlighting implications for treatment strategies in Latin America.

Abstract PS2-06-10: Pathologic Complete Response by Breast Cancer Molecular Subtype in a Colombian Cohort: Real-World Evidence from Latin America

Key Points

Discussion

Implication

Cite This Study

Abstract PS2-06-10: Pathologic Complete Response by Breast Cancer Molecular Subtype in a Colombian Cohort: Real-World Evidence from Latin America

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider